SKYE

Skye Bioscience Inc

0.7005

Jul 02 • 04:00PM ET +0.0253 (3.75%)

Healthcare Biotechnology USA Nano NASD

Peers: APLM BRNS CRVO GRDX IGC LSTA NRSN PLRZ SER SNTI

| Held by: VTI VXF

Scroll to Statements

Index	-
Market Cap	24.62M
Enterprise Value	7.82M
Income	-57.33M
Sales	0.00M
Book/sh	0.26
Cash/sh	0.49
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	12
IPO	Nov 26, 2014

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	2.73
P/C	1.44
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	1.78
Current Ratio	1.78
Debt/Eq	0.03
LT Debt/Eq	0.00
Option/Short	Yes / Yes

EPS (ttm)	-1.45
EPS next Y	-1.09
EPS next Q	-0.25
EPS this Y	33.33%
EPS next Y	-16.26%
EPS next 5Y	5.13%
EPS past 3/5Y	45.62% 28.34%
Sales past 3/5Y	- -
EPS Y/Y TTM	-74.39%
Sales Y/Y TTM	-
EPS Q/Q	-12.57%
Sales Q/Q	-
Earnings	May 11 AMC
EPS/Sales Surpr.	-3.73% -

Insider Own	34.65%
Insider Trans	0.00%
Inst Own	12.64%
Inst Trans	-0.35%
ROA	-136.16%
ROE	-167.97%
ROIC	-636.18%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-3.23%
SMA50	-11.83%
SMA200	-40.55%
Trades

Shs Outstand	35.13M
Shs Float	22.97M
Short Float	4.24%
Short Ratio	5.30
Short Interest	0.97M
52W High	4.99 -85.96%
52W Low	0.57 23.87%
Volatility	6.34% 7.75%
ATR (14)	0.06
RSI (14)	45.22
Beta	2.95
Rel Volume	0.60
Avg Volume	183.77K
Volume	109,458

Perf Week	-1.12%
Perf Month	-1.86%
Perf Quarter	5.35%
Perf Half Y	-3.65%
Perf YTD	-6.56%
Perf Year	-83.20%
Perf 3Y	-86.85%
Perf 5Y	-98.19%
Perf 10Y	-99.49%
Recom	1.57
Target Price	7.33
Prev Close	0.68
Price	0.70
Change	3.75%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-06-25	Downgrade	Craig Hallum	Buy → Hold	$2
Oct-06-25	Downgrade	Cantor Fitzgerald	Overweight → Neutral	$2
Aug-15-25	Initiated	Evercore ISI	Outperform	$10
Feb-28-25	Initiated	William Blair	Outperform
Sep-30-24	Initiated	Scotiabank	Sector Outperform	$20
Sep-10-24	Initiated	JMP Securities	Mkt Outperform	$15
Jul-09-24	Initiated	Craig Hallum	Buy	$18
May-23-24	Initiated	Cantor Fitzgerald	Overweight	$21
Apr-12-24	Initiated	Oppenheimer	Outperform	$25

May-20-26 07:00AM	Skye Announces Cohort Review Committee Approved Opening of Cohort 2 Based on Favorable Safety Data from First Four Participants Treated in Cohort 1 (GlobeNewswire) +6.04%
May-12-26 01:33PM	UPDATE - Skye Bioscience Reports First Quarter 2026 Financial Results and Business Update (GlobeNewswire) -7.56%
May-11-26 04:01PM	Skye Bioscience Reports First Quarter 2026 Financial Results and Business Update (GlobeNewswire)
Apr-07-26 07:00AM	Skye Bioscience Presenting at GLP-1-Based Therapeutics Summit (GlobeNewswire)
Apr-02-26 07:00AM	Skye Bioscience Treats First Patient in Nimacimab Higher-Dose Expansion Study Evaluating Exposure-Response to Inform Phase 2b Dose Selection for GLP-1 Combination Development (GlobeNewswire)
09:04PM	Loading…
Mar-11-26 09:04PM	Skye Bioscience Inc (SKYE) Q4 2025 Earnings Call Highlights: Pioneering Advances in Obesity ... (GuruFocus.com) -9.70%
Mar-10-26 04:01PM	Skye Bioscience Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update (GlobeNewswire) +10.33%
Mar-05-26 07:00AM	Skye Bioscience to Announce 2025 Financial Results and Business Update on March 10, 2026 (GlobeNewswire)
Feb-02-26 01:26PM	Penny Stock Skye Bioscience Drug Combo With Wegovy Shows Over 22% Weight Loss After One Year (Benzinga) -7.92%
07:00AM	Skye Reports Positive CBeyond Phase 2a Extension Interim Study Results for Nimacimab in Combination With Semaglutide (GlobeNewswire)
Jan-29-26 07:00AM	Skye Bioscience Highlights Attributes of its Peripherally-restricted CB1 Inhibitor Antibody at Keystone Obesity Conference (GlobeNewswire)
Jan-21-26 07:00AM	Skye Bioscience to Present Poster at Keystone Obesity Conference (GlobeNewswire)
Jan-14-26 03:32AM	Skye Bioscience, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SKYE (PR Newswire)
Jan-12-26 07:00AM	Skye Provides 2026 Corporate Outlook (GlobeNewswire)
Jan-06-26 09:00AM	Skye Bioscience, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before January 16, 2026 to Discuss Your Rights - SKYE (PR Newswire) +17.73%
07:00AM	Loading…
Jan-05-26 07:00AM	Halozyme and Skye Bioscience Announce Global Collaboration and License Agreement to Evaluate Nimacimab Co-Formulated with ENHANZE for Obesity (PR Newswire)
Dec-29-25 01:25AM	Skye Bioscience, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SKYE (PR Newswire)
Dec-19-25 02:56PM	Did You Suffer Financial Loss in Skye Bioscience, Inc.? Stockholders Should Contact Robbins LLP for Information About Their Rights Against SKYE. (Business Wire) -6.99%
Dec-11-25 07:44AM	Skye Bioscience, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SKYE (PR Newswire)
Dec-08-25 02:55AM	Skye Bioscience, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SKYE (PR Newswire)
Dec-02-25 09:00AM	Investors in Skye Bioscience, Inc. Should Contact Levi & Korsinsky Before January 16, 2026 to Discuss Your Rights - SKYE (PR Newswire) -8.26%
Dec-01-25 03:40AM	Skye Bioscience, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SKYE (PR Newswire) -7.63%
Nov-26-25 08:00AM	Skye Bioscience, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights SKYE (Business Wire)
Nov-24-25 07:00AM	Skye Bioscience to Participate in Upcoming Investment Conferences (Newsfile) +11.59%
Nov-11-25 12:01AM	Skye Bioscience Inc (SKYE) Q3 2025 Earnings Call Highlights: Promising Study Results and ... (GuruFocus.com)
Nov-10-25 04:01PM	Skye Bioscience Reports Third Quarter 2025 Financial Results and Business Update (GlobeNewswire) -7.19%
Nov-05-25 07:05AM	Skye Bioscience Late-Breaking Oral Abstract at ObesityWeek 2025 to Highlight Improvement in Rebound Weight Gain (GlobeNewswire) +6.34%
07:00AM	Skye Bioscience to Announce Third Quarter 2025 Financial Results and Business Update on November 10, 2025 (GlobeNewswire)
Oct-07-25 11:32AM	SKYE Stock Plunges 60% as Obesity Candidate Misses Key Phase II Goal (Zacks) -12.63%
Oct-06-25 07:00AM	Skye Bioscience Reports Topline CBeyond Phase 2a Data from Nimacimab Monotherapy and Combination Clinical Trial (GlobeNewswire) -60.00%
06:09AM	Loading…
06:09AM	Skye shares crash as obesity drug falls short in key study (BioPharma Dive)
Sep-19-25 02:19PM	Could This New Drug Be The Safer Way To Fight Obesity? (Benzinga)
07:00AM	Skye Presents Phase 1b Data for its Peripheral CB1-inhibiting Antibody, Nimacimab, at European Association for the Study of Diabetes (EASD) Annual Meeting (GlobeNewswire)
Sep-04-25 07:00AM	Skye's CB1 Inhibitor, Nimacimab, Demonstrates Superior Weight Loss and Differentiated Mechanisms from Monlunabant, and Continues to Show Enhanced Combination with Tirzepatide with Durable Post-Treatment Weight Maintenance in DIO Model (GlobeNewswire) +11.61%
Sep-02-25 07:00AM	Skye Completes 26-week Treatment Phase in Phase 2a CBeyond Study (GlobeNewswire)
Aug-27-25 07:00AM	Skye Bioscience to Host Virtual KOL Event and Provide Perspectives on Upcoming CBeyond Phase 2a Topline Clinical Data Readout (GlobeNewswire)
Aug-21-25 07:00AM	Skye Bioscience to Participate in Upcoming Investment and Medical Conferences (GlobeNewswire)
Aug-08-25 07:00AM	Skye Bioscience Inc (SKYE) Q2 2025 Earnings Call Highlights: Promising Trial Progress Amid ... (GuruFocus.com)
Aug-07-25 04:01PM	Skye Bioscience Reports Second Quarter 2025 Financial Results and Business Update (GlobeNewswire) -8.74%
Jul-30-25 07:00AM	Skye Bioscience to Announce Second Quarter 2025 Financial Results and Business Update on August 7, 2025 (GlobeNewswire)
Jul-06-25 04:01AM	Skye Bioscience Highlights Nimacimab's Promise in Obesity Treatment, Anticipates Phase 2a Data (Insider Monkey)
Jun-23-25 07:00AM	Skye Bioscience Shares Nimacimab "Anatomy of Progress" Video Series and Highlights Preclinical CB1 Antibody Data Presented at the American Diabetes Association's 85th Scientific Sessions (GlobeNewswire) +32.87%
Jun-22-25 06:15AM	Analysts Predict Up to ~590% Spike for These 2 Strong Buy Penny Stocks (TipRanks)
Jun-17-25 07:00AM	Skye Bioscience to Present Expanded Preclinical CB1 Antibody Data at the American Diabetes Association's 85th Scientific Sessions (GlobeNewswire)
May-23-25 11:13AM	3 Stocks Targeting Weight Loss Market With Cannabinoid-Based Therapies (Zacks) -8.21%
May-22-25 07:00AM	Skye Bioscience to Participate in Upcoming Investment Conferences (GlobeNewswire) -6.33%
May-19-25 05:00AM	Skye Bioscience Establishes Partnership with Arecor Therapeutics to Develop Enhanced Formulation of Obesity Candidate Nimacimab (GlobeNewswire) +14.97%
May-13-25 04:05PM	Skye Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -5.37%
07:00AM	Skye Bioscience Clinical Model Demonstrating Necessity of Peripheral CB1 Inhibition for Weight Loss Presented at European Congress on Obesity (GlobeNewswire)
May-09-25 03:40AM	Skye Bioscience Inc (SKYE) Q1 2025 Earnings Call Highlights: Promising Trial Progress and ... (GuruFocus.com)
May-08-25 04:01PM	Skye Bioscience Reports First Quarter 2025 Results and Highlights Nimacimab Differentiation in Obesity (GlobeNewswire)
May-07-25 07:00AM	Skye Bioscience to Announce 2025 First Quarter Financial Results on May 8th, 2025 (GlobeNewswire)
Apr-29-25 07:00AM	Skye Bioscience to Participate in May Investment and Medical Conferences (GlobeNewswire)
Apr-25-25 08:06PM	Skye Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-16-25 07:50AM	A Weight Loss Drug Candidate Essentially For Free As Skye Bioscience Is Trading At Cash Value (Seeking Alpha) -7.60%
Apr-15-25 07:00AM	Skye Bioscience Demonstrates Over 30% Weight Loss with Nimacimab and Tirzepatide Combination in Preclinical Model (GlobeNewswire) +30.53%
Apr-14-25 07:00AM	Skye Bioscience to Conduct Meetings at Piper Sandler Conference (GlobeNewswire) -7.09%
Mar-20-25 09:59PM	Skye Bioscience accelerates nimacimab clinical trial timeline with early enrollment and extended treatment period (SeekingAlpha) -5.50% +19.05%
09:58PM	Skye Bioscience, Inc. (SKYE) Q4 2024 Earnings Call Transcript (SeekingAlpha)
04:01PM	Skye Bioscience Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update (GlobeNewswire)
10:00AM	Here are the major earnings after the close today (SeekingAlpha)
Mar-19-25 05:35PM	Skye Bioscience Q4 2024 Earnings Preview (SeekingAlpha) -12.66%
Mar-14-25 07:00AM	Skye Bioscience to Announce 2024 Financial Results on March 20th, 2025 (GlobeNewswire)
Feb-27-25 06:00PM	Skye Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +6.34%
Feb-24-25 07:00AM	Skye Bioscience to Participate in SXSW Session on Obesity (GlobeNewswire)
Feb-20-25 07:00AM	Skye Bioscience to Present at TD Cowen Health Care Conference (GlobeNewswire)
Feb-04-25 07:00AM	Skye Bioscience Announces Participation in February Conferences (GlobeNewswire)
Jan-13-25 07:00AM	Skye Bioscience Provides 2025 Look Ahead and Year in Review (GlobeNewswire)
Dec-19-24 07:00AM	Skye Bioscience to Present at J.P. Morgan Healthcare Conference (GlobeNewswire)
Nov-18-24 07:00AM	Skye Bioscience to Participate in Upcoming December Healthcare Investment Conferences (GlobeNewswire) -7.88%
Nov-15-24 07:45AM	Skye Bioscience achieved more than 50% targeted patient enrollment in CBeyond (TipRanks) -10.16%
Nov-14-24 07:00AM	Skye Bioscience Surpasses 50% Patient Enrollment in Phase 2 Obesity Study of Differentiated CB1 Inhibitor (GlobeNewswire)
Nov-07-24 04:01PM	Skye Bioscience Reports Third Quarter 2024 Financial Results and Recent Highlights (GlobeNewswire)
Nov-04-24 07:00AM	Skye Bioscience Demonstrates Prominent Role of Peripheral CB1 Inhibition and Achieves Significant Weight Loss with Novel CB1-inhibiting Antibody, Nimacimab, in Preclinical Model (GlobeNewswire)
Nov-01-24 07:00AM	Skye Bioscience to Announce Third Quarter 2024 Results (GlobeNewswire) +6.11%
Oct-29-24 07:00AM	Skye Bioscience Names Independent Director Paul Grayson as Chairman of the Board (GlobeNewswire)
Oct-21-24 07:00AM	Skye Bioscience to Participate in Upcoming November Healthcare Investment Conferences (GlobeNewswire)
Sep-23-24 07:00AM	Skye Bioscience Comments on Monlunabant Phase 2 Top-line Data and Reiterates Confidence in Nimacimab Clinical Development Plan (GlobeNewswire) +11.15%
Sep-03-24 07:00AM	Skye Bioscience Appoints Puneet S. Arora, MD, as Chief Medical Officer (GlobeNewswire)
Aug-26-24 07:00AM	Skye Bioscience to Participate in Upcoming Healthcare Investment Conferences (GlobeNewswire) +15.29%
Aug-23-24 06:45PM	Skye Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +12.69%
Aug-22-24 07:00AM	Skye Bioscience Launches Phase 2 CBeyond Clinical Trial of its Differentiated CB1 Inhibitor, Nimacimab, in Patients with Obesity (GlobeNewswire)
Aug-09-24 05:59PM	Skye Bioscience Reports Second Quarter 2024 Financial Results and Recent Highlights (GlobeNewswire) -9.42%
Jul-24-24 07:30AM	Beacon Biosignals Announces Strategic Collaboration with Skye Bioscience to Integrate Sleep Quality and Sleep Apnea Endpoints in CBEYOND Phase 2 Trial of Nimacimab for Obesity (GlobeNewswire)
06:00AM	Skye Bioscience Hosts Virtual KOL Event, "Metabolic Rewiring with CB1 Inhibition," and Details Phase 2 Nimacimab Clinical Trial Design Including Obstructive Sleep Apnea Exploratory Endpoints (GlobeNewswire)
Jul-11-24 07:15AM	Skye Bioscience to Host Virtual KOL Event, Metabolic Rewiring with CB1 Inhibition, on July 24th (GlobeNewswire) +6.90%
07:00AM	Skye Bioscience Establishes Metabolic Clinical and Scientific Advisory Board to Support Development of Nimacimab (GlobeNewswire)
Jul-03-24 07:00AM	Skye Bioscience Appoints Dr. Karen Smith to Board of Directors (GlobeNewswire)
Jul-01-24 11:13AM	Google DeepMind CEO: 'This Is the Next $100 Billion AI Business' (InvestorPlace)
07:00AM	Skye Bioscience Added to Russell 2000 and Russell 3000 Indexes (GlobeNewswire)
Jun-25-24 07:00AM	Skye BioScience Participating in Piper Sandler Virtual Obesity Day (GlobeNewswire) -6.19%
Jun-10-24 08:22AM	Skye Bioscience ends eye disease R&D efforts after glaucoma drug's phase 2 fail (FierceBiotech.com) -8.78%
07:00AM	Skye Concentrates Strategy and Clinical Development Focus on Nimacimab Metabolic Program (GlobeNewswire)
Jun-03-24 07:00AM	Skye Bioscience to Present at Jefferies Global Healthcare Conference (GlobeNewswire)
May-17-24 04:12PM	Google DeepMind CEO: 'This Is the Next $100 Billion AI Business' (InvestorPlace)
May-10-24 07:00AM	Skye Bioscience Highlights Novel Synthetic Cannabinoid-based Library Capable of Modulating the Endocannabinoid System to Treat Ocular Diseases at ARVO 2024 Annual Meeting (GlobeNewswire) -6.21%
May-07-24 11:59AM	Skye Bioscience Moves to Nasdaq, Hits Milestone in Clinical Program (News Direct)
Apr-30-24 07:00AM	Skye Bioscience to Present Two Posters at Association for Research in Vision and Ophthalmology (ARVO) 2024 Annual Meeting (GlobeNewswire)
Apr-23-24 07:00AM	Skye Bioscience to Present at Upcoming Investment Conferences (GlobeNewswire) -5.27%
Apr-10-24 08:00AM	Skye Bioscience Uplists to The Nasdaq Global Market (GlobeNewswire) +39.69%

Skye Bioscience, Inc. is a clinical stage biopharmaceutical company, which engages in the development of new medicines that unlock the pharmaceutical potential of the endocannabinoid system to treat diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration. Its products include nimacimab and SBI-100 Ophthalmic Emulsion. The company was founded on March 16, 2011 and is headquartered in San Diego, CA.

PresidentMr. Punit S. Dhillon B.A.

Chief Operating OfficerMr. Tu Diep M.Sc.

CFO and Principal Financial & Accounting OfficerMr. John P. Sharp CPA

Chief Scientific OfficerDr. Christopher G. Twitty Ph.D.

M.D.Dr. Puneet S. Arora FACE

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Schwab Andrew J.	Director	Aug 22 '25	Sale	3.42	170,449	582,936	57,493	Aug 22 07:07 PM
Schwab Andrew J.	Director	Aug 21 '25	Sale	3.57	60,956	217,613	63,963	Aug 22 07:07 PM
5AM Partners VII, LLC	10% Owner	Aug 22 '25	Sale	3.42	170,449	582,936	57,493	Aug 22 07:05 PM
5AM Partners VII, LLC	10% Owner	Aug 21 '25	Sale	3.57	60,956	217,613	63,963	Aug 22 07:05 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

$100 Off Your First Year Get Elite For Just $199.50

SKYE

Skye Bioscience Inc

Upgrade your Finviz experience